Loading
A phase 2 trial of PM8002, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07680764 by Bristol-Myers Squibb, with 160 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-09-15. Interventions recorded: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares PM8002, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/